GlassScriptPhysician profile
Emerson Chang
NPI 1710127741
$756.05
in general payments reported to CMS, 2019-2025
18 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.83 · 2022: $18.46 · 2023: $38.05 · 2024: $16.51 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $87.10 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $84.86 | 2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $68.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $66.24 | 2025 | Breztri, Airsupra |
| Lilly USA, LLC | $58.85 | 2022-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.59 | 2025 | Jardiance |
| Astellas Pharma US INC | $54.56 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.43 | 2025 | Xifaxan |
| Dexcom, INC. | $40.22 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $38.45 | 2025 | |
| Gilead Sciences, INC. | $23.70 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $22.04 | 2025 | Eliquis |
| Vivus LLC | $20.83 | 2021 | |
| Alk-Abello, INC | $20.55 | 2025 | Neffy |
| Exact Sciences Corporation | $19.88 | 2025 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $18.98 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $17.61 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.17 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emerson Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.